INNOGEN-B (02591) core product included in the "National Medical Insurance Drug List"
Yinuo Medicine-B (02591) announced that the group's core product (ie. Ipragliflozin) has been successfully included in the latest version of China's National Reimbursement Drug List (2025 Edition) for the treatment of type 2 diabetes ("T2D") indications. The latest version of the National Reimbursement Drug List will officially take effect on January 1, 2026.
INNOGEN-B (02591) announces that the group's core product (i.e. exenatide alpha) has successfully been included in the latest version of China's National Drug Reimbursement List (2025 edition) for the treatment of type 2 diabetes ("T2D"). The latest version of the National Drug Reimbursement List will officially take effect on January 1, 2026.
Related Articles
Industrial Market Strategy for 2026: Fierce Competition, Comprehensive Bull Market Sets Sail
Original YuanChuang Group (001325.SZ) IPO price set at 24.75 yuan per share, subscription to start on December 9th.
Improved YuanChuang Group (001325.SZ) sets IPO price at 24.75 yuan per share, subscription to begin on December 9th.
China National Chemical Engineering (601117.SH): Nylon new material project reaches production.
Industrial Market Strategy for 2026: Fierce Competition, Comprehensive Bull Market Sets Sail
Original YuanChuang Group (001325.SZ) IPO price set at 24.75 yuan per share, subscription to start on December 9th.
Improved YuanChuang Group (001325.SZ) sets IPO price at 24.75 yuan per share, subscription to begin on December 9th.
China National Chemical Engineering (601117.SH): Nylon new material project reaches production.
